Business Wire

DE-CSC

12.2.2024 14:01:29 CET | Business Wire | Press release

Share
CSC Partners with NetDiligence to Help Mitigate Cyber Risks and Support the Cyber Insurance Ecosystem

CSC, an enterprise-class domain registrar and world leader in mitigating domain security, domain name system (DNS), and digital brand threats, today announces its partnership with NetDiligence®, a leader in cyber risk readiness and response solutions for the cyber insurance industry. With this agreement, CSC is now an available vendor to cyber insurance carriers, brokers, and clients on NetDiligence’s eRiskHub® under the newly developed “pre-breach” category: brand protection and domain security.

CSC’s innovative technology allows cyber insurance carriers, brokers, and clients alike to proactively protect their businesses against cyber threats and online brand abuse. “As a preferred vendor to cyber insurance leaders, it’s critical to address cybersecurity gaps and help companies keep losses at a minimum,” says Mark Greisiger, president of NetDiligence. “We’re excited to introduce CSC’s domain security and digital brand protection solutions on our eRiskHub platform because it will provide our users with new ways to address risk and cyber threats such as phishing, business email compromise, and ransomware.”

An overwhelming majority of companies overlook their domain security posture as part of a larger risk management plan for their business. For corporations operating multiple brands—with hundreds or even thousands of domains within their portfolios—it’s crucial to have rapid detection and deactivation of confusingly similar domains imitating brands, as well as any compromised, hijacked domains, or subdomains that may exist.

“As the world’s leading enterprise-class domain registrar, CSC can detect domain threats, online brand and DNS abuse, and fraud quickly to protect companies from fraudulent or compromised domains that lead to devastating cyber attacks,” says Mark Calandra, president of CSC’s Digital Brand Services division. “Our inclusion in eRiskHub creates visibility for our services directly within the workflow of users looking to optimize their cyber security posture.”

Within the eRiskHub, CSC’s solutions will be categorized into three services: digital brand protection, domain registrar services, and fraud protection. To access pre-breach brand protection and domain security solutions, visit the eRiskHub. Additionally, on February 12 at 11:30 a.m., CSC’s Digital Brand Services Chief Technology Officer Ihab Shraim and AXA XL’s Gwenn Cujdik, North America Cyber Incident Response Team, will be speaking on the Pathways to Resilience panel, Domain Security: Addressing Cybersecurity at the Source of the Problem. To contact CSC directly, visit cscdbs.com.

About CSC

CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSecSM platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia- Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

About NetDiligence

NetDiligence® specializes in Cyber Risk Readiness & Response services. With over 20 years of experience in cyber, NetDiligence is an award-winning provider of innovative cyber risk management software and services to the insurance industry, including QuietAudit® Cyber Risk Assessments, the eRiskHub® cyber risk management portal, their authorized Breach Coach® program, and Breach Plan Connect®, a securely hosted solution designed to help senior managers plan and execute their organization’s response to a cyber incident, which also includes a free mobile app for convenient access and alternative means of communication if company systems are compromised. NetDiligence publishes an annual Cyber Claims Study and traditionally hosts their Cyber Risk Summit conferences in Philadelphia, California, Toronto, Florida, London, and Bermuda. For more information, visit NetDiligence.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212855330/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye